Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Retinal Biologics Market, by Indication
1.4.2 Global Retinal Biologics Market, by Drug Class
1.4.3 Global Retinal Biologics Market, by Distribution Channel
1.4.4 Global Retinal Biologics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies deployed in Retinal Biologics Market
Chapter 5. Global Retinal Biologics Market by Indication
5.1 Global Macular Degeneration Market by Region
5.2 Global Diabetic Retinopathy Market by Region
5.3 Global Others Market by Region
Chapter 6. Global Retinal Biologics Market by Drug Class
6.1 Global VEGF-A Antagonist Market by Region
6.2 Global Others Market by Region
Chapter 7. Global Retinal Biologics Market by Distribution Channel
7.1 Global Hospital Pharmacy Market by Region
7.2 Global Retail Pharmacy Market by Region
7.3 Global Online Pharmacy Market by Region
Chapter 8. Global Retinal Biologics Market by Region
8.1 North America Retinal Biologics Market
8.1.1 North America Retinal Biologics Market by Indication
8.1.1.1 North America Macular Degeneration Market by Country
8.1.1.2 North America Diabetic Retinopathy Market by Country
8.1.1.3 North America Others Market by Country
8.1.2 North America Retinal Biologics Market by Drug Class
8.1.2.1 North America VEGF-A Antagonist Market by Country
8.1.2.2 North America Others Market by Country
8.1.3 North America Retinal Biologics Market by Distribution Channel
8.1.3.1 North America Hospital Pharmacy Market by Country
8.1.3.2 North America Retail Pharmacy Market by Country
8.1.3.3 North America Online Pharmacy Market by Country
8.1.4 North America Retinal Biologics Market by Country
8.1.4.1 US Retinal Biologics Market
8.1.4.1.1 US Retinal Biologics Market by Indication
8.1.4.1.2 US Retinal Biologics Market by Drug Class
8.1.4.1.3 US Retinal Biologics Market by Distribution Channel
8.1.4.2 Canada Retinal Biologics Market
8.1.4.2.1 Canada Retinal Biologics Market by Indication
8.1.4.2.2 Canada Retinal Biologics Market by Drug Class
8.1.4.2.3 Canada Retinal Biologics Market by Distribution Channel
8.1.4.3 Mexico Retinal Biologics Market
8.1.4.3.1 Mexico Retinal Biologics Market by Indication
8.1.4.3.2 Mexico Retinal Biologics Market by Drug Class
8.1.4.3.3 Mexico Retinal Biologics Market by Distribution Channel
8.1.4.4 Rest of North America Retinal Biologics Market
8.1.4.4.1 Rest of North America Retinal Biologics Market by Indication
8.1.4.4.2 Rest of North America Retinal Biologics Market by Drug Class
8.1.4.4.3 Rest of North America Retinal Biologics Market by Distribution Channel
8.2 Europe Retinal Biologics Market
8.2.1 Europe Retinal Biologics Market by Indication
8.2.1.1 Europe Macular Degeneration Market by Country
8.2.1.2 Europe Diabetic Retinopathy Market by Country
8.2.1.3 Europe Others Market by Country
8.2.2 Europe Retinal Biologics Market by Drug Class
8.2.2.1 Europe VEGF-A Antagonist Market by Country
8.2.2.2 Europe Others Market by Country
8.2.3 Europe Retinal Biologics Market by Distribution Channel
8.2.3.1 Europe Hospital Pharmacy Market by Country
8.2.3.2 Europe Retail Pharmacy Market by Country
8.2.3.3 Europe Online Pharmacy Market by Country
8.2.4 Europe Retinal Biologics Market by Country
8.2.4.1 Germany Retinal Biologics Market
8.2.4.1.1 Germany Retinal Biologics Market by Indication
8.2.4.1.2 Germany Retinal Biologics Market by Drug Class
8.2.4.1.3 Germany Retinal Biologics Market by Distribution Channel
8.2.4.2 UK Retinal Biologics Market
8.2.4.2.1 UK Retinal Biologics Market by Indication
8.2.4.2.2 UK Retinal Biologics Market by Drug Class
8.2.4.2.3 UK Retinal Biologics Market by Distribution Channel
8.2.4.3 France Retinal Biologics Market
8.2.4.3.1 France Retinal Biologics Market by Indication
8.2.4.3.2 France Retinal Biologics Market by Drug Class
8.2.4.3.3 France Retinal Biologics Market by Distribution Channel
8.2.4.4 Russia Retinal Biologics Market
8.2.4.4.1 Russia Retinal Biologics Market by Indication
8.2.4.4.2 Russia Retinal Biologics Market by Drug Class
8.2.4.4.3 Russia Retinal Biologics Market by Distribution Channel
8.2.4.5 Spain Retinal Biologics Market
8.2.4.5.1 Spain Retinal Biologics Market by Indication
8.2.4.5.2 Spain Retinal Biologics Market by Drug Class
8.2.4.5.3 Spain Retinal Biologics Market by Distribution Channel
8.2.4.6 Italy Retinal Biologics Market
8.2.4.6.1 Italy Retinal Biologics Market by Indication
8.2.4.6.2 Italy Retinal Biologics Market by Drug Class
8.2.4.6.3 Italy Retinal Biologics Market by Distribution Channel
8.2.4.7 Rest of Europe Retinal Biologics Market
8.2.4.7.1 Rest of Europe Retinal Biologics Market by Indication
8.2.4.7.2 Rest of Europe Retinal Biologics Market by Drug Class
8.2.4.7.3 Rest of Europe Retinal Biologics Market by Distribution Channel
8.3 Asia Pacific Retinal Biologics Market
8.3.1 Asia Pacific Retinal Biologics Market by Indication
8.3.1.1 Asia Pacific Macular Degeneration Market by Country
8.3.1.2 Asia Pacific Diabetic Retinopathy Market by Country
8.3.1.3 Asia Pacific Others Market by Country
8.3.2 Asia Pacific Retinal Biologics Market by Drug Class
8.3.2.1 Asia Pacific VEGF-A Antagonist Market by Country
8.3.2.2 Asia Pacific Others Market by Country
8.3.3 Asia Pacific Retinal Biologics Market by Distribution Channel
8.3.3.1 Asia Pacific Hospital Pharmacy Market by Country
8.3.3.2 Asia Pacific Retail Pharmacy Market by Country
8.3.3.3 Asia Pacific Online Pharmacy Market by Country
8.3.4 Asia Pacific Retinal Biologics Market by Country
8.3.4.1 China Retinal Biologics Market
8.3.4.1.1 China Retinal Biologics Market by Indication
8.3.4.1.2 China Retinal Biologics Market by Drug Class
8.3.4.1.3 China Retinal Biologics Market by Distribution Channel
8.3.4.2 Japan Retinal Biologics Market
8.3.4.2.1 Japan Retinal Biologics Market by Indication
8.3.4.2.2 Japan Retinal Biologics Market by Drug Class
8.3.4.2.3 Japan Retinal Biologics Market by Distribution Channel
8.3.4.3 India Retinal Biologics Market
8.3.4.3.1 India Retinal Biologics Market by Indication
8.3.4.3.2 India Retinal Biologics Market by Drug Class
8.3.4.3.3 India Retinal Biologics Market by Distribution Channel
8.3.4.4 South Korea Retinal Biologics Market
8.3.4.4.1 South Korea Retinal Biologics Market by Indication
8.3.4.4.2 South Korea Retinal Biologics Market by Drug Class
8.3.4.4.3 South Korea Retinal Biologics Market by Distribution Channel
8.3.4.5 Singapore Retinal Biologics Market
8.3.4.5.1 Singapore Retinal Biologics Market by Indication
8.3.4.5.2 Singapore Retinal Biologics Market by Drug Class
8.3.4.5.3 Singapore Retinal Biologics Market by Distribution Channel
8.3.4.6 Malaysia Retinal Biologics Market
8.3.4.6.1 Malaysia Retinal Biologics Market by Indication
8.3.4.6.2 Malaysia Retinal Biologics Market by Drug Class
8.3.4.6.3 Malaysia Retinal Biologics Market by Distribution Channel
8.3.4.7 Rest of Asia Pacific Retinal Biologics Market
8.3.4.7.1 Rest of Asia Pacific Retinal Biologics Market by Indication
8.3.4.7.2 Rest of Asia Pacific Retinal Biologics Market by Drug Class
8.3.4.7.3 Rest of Asia Pacific Retinal Biologics Market by Distribution Channel
8.4 LAMEA Retinal Biologics Market
8.4.1 LAMEA Retinal Biologics Market by Indication
8.4.1.1 LAMEA Macular Degeneration Market by Country
8.4.1.2 LAMEA Diabetic Retinopathy Market by Country
8.4.1.3 LAMEA Others Market by Country
8.4.2 LAMEA Retinal Biologics Market by Drug Class
8.4.2.1 LAMEA VEGF-A Antagonist Market by Country
8.4.2.2 LAMEA Others Market by Country
8.4.3 LAMEA Retinal Biologics Market by Distribution Channel
8.4.3.1 LAMEA Hospital Pharmacy Market by Country
8.4.3.2 LAMEA Retail Pharmacy Market by Country
8.4.3.3 LAMEA Online Pharmacy Market by Country
8.4.4 LAMEA Retinal Biologics Market by Country
8.4.4.1 Brazil Retinal Biologics Market
8.4.4.1.1 Brazil Retinal Biologics Market by Indication
8.4.4.1.2 Brazil Retinal Biologics Market by Drug Class
8.4.4.1.3 Brazil Retinal Biologics Market by Distribution Channel
8.4.4.2 Argentina Retinal Biologics Market
8.4.4.2.1 Argentina Retinal Biologics Market by Indication
8.4.4.2.2 Argentina Retinal Biologics Market by Drug Class
8.4.4.2.3 Argentina Retinal Biologics Market by Distribution Channel
8.4.4.3 UAE Retinal Biologics Market
8.4.4.3.1 UAE Retinal Biologics Market by Indication
8.4.4.3.2 UAE Retinal Biologics Market by Drug Class
8.4.4.3.3 UAE Retinal Biologics Market by Distribution Channel
8.4.4.4 Saudi Arabia Retinal Biologics Market
8.4.4.4.1 Saudi Arabia Retinal Biologics Market by Indication
8.4.4.4.2 Saudi Arabia Retinal Biologics Market by Drug Class
8.4.4.4.3 Saudi Arabia Retinal Biologics Market by Distribution Channel
8.4.4.5 South Africa Retinal Biologics Market
8.4.4.5.1 South Africa Retinal Biologics Market by Indication
8.4.4.5.2 South Africa Retinal Biologics Market by Drug Class
8.4.4.5.3 South Africa Retinal Biologics Market by Distribution Channel
8.4.4.6 Nigeria Retinal Biologics Market
8.4.4.6.1 Nigeria Retinal Biologics Market by Indication
8.4.4.6.2 Nigeria Retinal Biologics Market by Drug Class
8.4.4.6.3 Nigeria Retinal Biologics Market by Distribution Channel
8.4.4.7 Rest of LAMEA Retinal Biologics Market
8.4.4.7.1 Rest of LAMEA Retinal Biologics Market by Indication
8.4.4.7.2 Rest of LAMEA Retinal Biologics Market by Drug Class
8.4.4.7.3 Rest of LAMEA Retinal Biologics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Novartis AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Amgen, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 AbbVie, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Approvals & Trials:
9.3.6 SWOT Analysis
9.4 Bayer AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 SWOT Analysis
9.5 Regeneron Pharmaceuticals, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Research & Development Expense
9.5.4 SWOT Analysis
9.6 Santen Pharmaceutical Co., Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 SWOT Analysis
9.7 Bausch Health Companies, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Approvals & Trials:
9.7.5.3 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Approvals & Trials:
9.8.6 SWOT Analysis
9.9 MeiraGTx Holdings plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 SWOT Analysis
9.1 Oxurion NV
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Research & Development Expenses
9.10.4 SWOT Analysis
Chapter 10. Winning Imperative for Retinal Biologics Market
Unique Offerings 
